Summary

Previously, the Randomized Evaluation of Long-Term Anticoagulation Therapy [RE-LY] trial evaluated two doses of dabigatran (110 and 150 mg BID; open dabigatran but blinded dose) versus warfarin (open-label) in patients with nonvalvular atrial fibrillation and at least 1 risk factor for stroke [Flaker et al. J Am Coll Cardiol 2012]. The goal of the RELY-ABLE extension study [NCT00808067] was to describe the long-term efficacy and safety of ongoing dabigatran therapy after the RE-LY trial.